Preparation of mGM-CSF/βhCG fusion protein and the effect of its sensitized DC vaccine on RM-1 prostate tumor in mice

CAO Rongyue; CHANG Na; LI Manman; WANG Yunkang; WU Di; SHI Baoying; YUAN Yuting; LONG Jun

doi:10.11665/j.issn.1000-5048.20150117

Journal of China Pharmaceutical University > 2015 > 46(1): 111-116. > DOI: 10.11665/j.issn.1000-5048.20150117

CAO Rongyue, CHANG Na, LI Manman, WANG Yunkang, WU Di, SHI Baoying, YUAN Yuting, LONG Jun. Preparation of mGM-CSF/βhCG fusion protein and the effect of its sensitized DC vaccine on RM-1 prostate tumor in mice[J]. Journal of China Pharmaceutical University, 2015, 46(1): 111-116. DOI: 10.11665/j.issn.1000-5048.20150117

Citation:

PDF (1636 KB)

Preparation of mGM-CSF/βhCG fusion protein and the effect of its sensitized DC vaccine on RM-1 prostate tumor in mice

More Information

Graphical Abstract

Abstract

Abstract

An expression vector pET-28a-mGM-CSF-X10-βhCGCTP37 plasmid containing the βhCG and mGM-CSF gene was designed and constructed. The fusion protein was induced by lactose and purified by ammonium sulfate precipitation and DEAE-cellulose anion exchange column. Then dendritic cells(DC)in C57BL/6J mice were extracted and sensitized by the fusion protein to obtain DC vaccine. The DC vaccine was inoculated to C57BL of / 6J mice with prostate cancer RM-1. The results indicated that the anti-tumor effects of DC group and DC combined with paclitaxel(DP)group were superior to that of paclitaxel(Pac)group(P< 0. 01), and the anti-tumor effect of DP group was better than that of DC group. Thus, the constructed DC vaccine can inhibit the growth of prostate cancer, and have synergistic anti-tumor when used with paclitaxel.
- βhCG,
- mGM-CSF,
- antitumor,
- prostate cancer,
- fusion protein,
- immunotherapy,
- dendritic cells

FullText(HTML)

References (13)

References

[1]	Small EJ,Fratesi P,Reese DM, et al.Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells[J].J Clin Oncol,2000,18(23):3894-3903.
[2]	Abdulla A,Kappoor A.Emerging novel therapies in the treatment of castrate-resistant prostate cancer[J].Can Urol Assoc J,2011,5(2):120-133.
[3]	Sims RB.Development of sipuleucel-T:autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer[J].Vaccine,2012,30(29):4394-4397.
[4]	Iles RK,Delves PJ,Butler SA.Does hCG or hCGβ play a role in cancer cell biology[J].Mol Cell Endocrinol,2010,329(1/2):62-70.
[5]	Cole LA.hCG,five independent molecules[J].Clin Chim Acta,2012,413(1/2):48-65.
[6]	Cole LA.Hyperglycosylated hCG,a review[J].Placenta,2010,31(8):653-664.
[7]	Cole LA,Butler S.Hyperglycosylated hCG,hCGβ and hyperglycosylated hCGβ:interchangeable cancer promoters[J].Mol Cell Endocrinol,2012, 349(2):232-238.
[8]	Cheng YC,Valero V,Davis ML, et al.Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients[J].Br J Cancer,2010,103(9):1331-1334.
[9]	Somani J,Lonial S,Rosenthal H, et al.A randomized,placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant:effect on cellular and humoral immune responses[J].Vaccine,2002,21(3/4):221-230.
[10]	Garcia F,Climent N,Assoumou L, et al.A therapeutic dendritic cell-based vaccine for HIV-1 infection[J].J Infect Dis,2011, 203(4):473-478.
[11]	Skalova K,Mollova K,Michalek J.Human myeloid dendritic cells for cancer therapy:does maturation matter[J]?Vaccine,2010,28(32):5153-5160.
[12]	Yin W,He Q,Hu Z, et al.A novel therapeutic vaccine of GM-CSF/TNFα surface-modified RM-1 cells against the orthotopic prostatic cancer[J].Vaccine,2010,28(31):4937-4944.
[13]	Inaba K,Inaba M,Romani N, et al.Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor[J].J Exp Med,1992, 176(6):1693-1702.

[1]	WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
[2]	SUN Liting, ZHANG Weiguo, TONG Yue. Research progress on targeted protein S-palmitoylation modification in T cell immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(1): 45-52. DOI: 10.11665/j.issn.1000-5048.2023112903
[3]	CUI Zhenzhen, ZHAO Yifan, SUN Yu, Meng Jiayi, KANG Di, HU Lihong. Research progress of drugs for cancer immunotherapy based on CCL2/CCR2 signaling axis[J]. Journal of China Pharmaceutical University, 2024, 55(1): 36-44. DOI: 10.11665/j.issn.1000-5048.2023112904
[4]	YAO Zheng, LI Zihan, GAO Liming, HU Xing, CHEN Yan, PAN Wenqi, LI Qian. Advances of research on CAR-T cell immunotherapy for solid tumors[J]. Journal of China Pharmaceutical University, 2021, 52(4): 496-504. DOI: 10.11665/j.issn.1000-5048.20210413
[5]	YU Zexuan, JU Caoyun, ZHANG Can. Construction and application of gene delivery systems for primary dendritic cells[J]. Journal of China Pharmaceutical University, 2021, 52(4): 438-446. DOI: 10.11665/j.issn.1000-5048.20210406
[6]	XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
[7]	JIANG Liangliang, JIANG Tao, LUO Jianhua, YAO Wenbing, TIAN Hong. A novel human immune system mice model for assessing the immunogenicity of cancer vaccines[J]. Journal of China Pharmaceutical University, 2019, 50(6): 734-742. DOI: 10.11665/j.issn.1000-5048.20190615
[8]	WANG Rui, WANG Yongmei, CAI Mingjun, KE Xuejia, WU Yue, CHONG Jun, CAO Rongyue. Pharmacological effects of anti-melanoma DC vaccine sensitized by fusion proteins of G3G6 and HST1[J]. Journal of China Pharmaceutical University, 2019, 50(2): 238-245. DOI: 10.11665/j.issn.1000-5048.20190216
[9]	ZHANG Rui, JIANG Tao, ZENG Tianzhu, YAO Wenbing, GAO Xiangdong, TIAN Hong. Advances of combined immunotherapy in tumor[J]. Journal of China Pharmaceutical University, 2018, 49(4): 383-391. DOI: 10.11665/j.issn.1000-5048.20180401
[10]	JING Liangliang, MIAO Zitao, LI Manman, YE Jia, JIN Liang, CAO Rongyue, LONG Jun. Anti-tumor effect and its mechanism of co-administration of fusion proteins hVEGF121/βhCG and mGM-CSF/βhCG[J]. Journal of China Pharmaceutical University, 2017, 48(1): 102-109. DOI: 10.11665/j.issn.1000-5048.20170116

Cited By

Get Citation

PDF

XML

Article views (1424) PDF downloads (2211)

Turn off MathJax

Article Contents

Abstract

References

Preparation of mGM-CSF/βhCG fusion protein and the effect of its sensitized DC vaccine on RM-1 prostate tumor in mice

Abstract

References

Related Articles

Catalog

Preparation of mGM-CSF/βhCG fusion protein and the effect of its sensitized DC vaccine on RM-1 prostate tumor in mice

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content